2370.TMEDINET Co., Ltd.
MEDINET Co., Ltd. has one year to prove it’s more than a biotech buzzword — the Q2 FY2027 earnings release on 2026-11-12 is the first real test, with a modeled bull target of $30.00 and a bear fallback of $23.00, leaning 64% toward the upside. From there, the regenerative medicine pipeline update on 2027-01-20, cross-border policy on 2027-04-06, and full-year guidance on 2027-05-13 form a sequence of escalating stakes, each with its own bull and bear path, all leaning bullish. The question is whether the company can keep the momentum alive through a year of high-stakes regulatory and operational tests.
The schedule
- Thu12Nov
Earnings release for Q2 FY2027, with potential guidance on future growth and pipeline progress.
- Wed20Jan
Update on the progress of regenerative medicine pipeline, which could influence investor sentiment.
- Tue6Apr
Potential policy changes affecting cross-border biotech operations, which could impact the company's operations.
- Thu13May
Full year earnings and guidance for FY2027, which could provide insight into the company's performance and future outlook.
